Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai-600036, Tamilnadu, India.
Nanomedicine (Lond). 2017 Dec;12(23):2675-2692. doi: 10.2217/nnm-2017-0236. Epub 2017 Nov 3.
Management of prostate cancer is currently being pursued by systemic delivery of anticancer drugs, but it has drawbacks like nonspecific distribution, decreased bioavailability, coupled with adverse side effects. These problems have been resolved using nanomedicine-based anticancer drug delivery to improve the therapeutic index with higher drug dose and reduced nonspecific distribution. Targeting prostate tumor by delivering nanomedicine through locoregional route is more effective, than the systemic delivery, which can decrease systemic exposure of the therapeutics significantly. Therefore, in this article, we have reviewed the current prospects and challenges of prostate cancer therapy using nanomedicine, by providing a comprehensive description of advantages and limitations of the systemic route and locoregional route. Eventually, we have emphasized on the need for localized prostate cancer therapy developments using nanomedicines.
目前，通过系统递送抗癌药物来治疗前列腺癌，但这种方法存在分布不均匀、生物利用度降低以及不良反应等缺点。为了解决这些问题，人们采用基于纳米医学的抗癌药物递送系统来提高治疗指数，增加药物剂量，减少非特异性分布。通过局部途径递送纳米药物靶向前列腺肿瘤比全身递送更有效，因为全身递送会显著降低药物的全身暴露。因此，在本文中，我们通过全面描述全身和局部途径的优缺点，综述了纳米医学治疗前列腺癌的现状和挑战。最终，我们强调了使用纳米药物进行局部前列腺癌治疗开发的必要性。
